SYK and B-cell chronic lymphocytic leukemia: Thus, pharmacological targeting of Syk is effective in affecting the signal transduction of B-cell receptors, leading to cell apoptosis and inhibition of the activation and migration of B-cells, which are therapeutic targets for B-cell dominant diseases, such as chronic lymphocytic leukemia, B-cell malignancies, and autoimmune disorders (Buchner et al., 2010; Hoellenriegel et al., 2012).